Department of Life and Environmental Sciences, Unit of Pharmaceutical, Pharmacological and Nutraceutical Sciences, University of Cagliari, via Ospedale 72, Cagliari I, 09124, Italy.
Department NEUROFARBA - Pharmaceutical and Nutraceutical Section, University of Firenze, via Ugo Schiff 6, I-50019, Sesto Fiorentino, Firenze, Italy.
Eur J Med Chem. 2019 Nov 15;182:111638. doi: 10.1016/j.ejmech.2019.111638. Epub 2019 Aug 22.
Four new series of aromatic sulfamates were synthesized and investigated for the inhibition of four human (h) isoforms of zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1), hCA I, II, IX, and XII. The reported derivatives, obtained by a sulfamoylation reaction of the corresponding phenolic precursors, bear 3,5-diarylpyrazoline moieties as spacers between the benzenesulfamate fragment which binds the zinc ion from the active site, and the tail of the inhibitor. Pyrazolines are biologically privileged scaffolds, endowed with versatile biological activity, such as an anti-proliferative action. The derivatives were tested for the inhibition of the cytosolic, hCA I and II (off target isoforms) and the trans-membrane, tumor-associated hCA IX and XII enzymes (anticancer drug targets). Generally, hCA I was not effectively inhibited, whereas many low nanomolar inhibitors were evidenced against hCA II (KIs in the range of 0.42-90.1 nM), IX (KIs in the range of 0.72-63.6 nM), and XII (KIs in the range of 0.88-85.2 nM). The best substitution fragments at the pyrazoline ring included for CA II a 4-sulfamic group on the 3-aryl and halogens on the 5-aryl or a methoxy group on the 3-aryl and a 4-sulfamate group on the 5-aryl; for CA IX and CA XII they included the sulfamic group on the 3- or 4-position of the 5-aryl and an electronwithdrawing group on the 4-postion of the 3-aryl ring.
合成了四个新系列的芳基磺酸盐,并研究了它们对四种人源锌酶碳酸酐酶(CA,EC 4.2.1.1)同工酶 hCA I、hCA II、hCA IX 和 hCA XII 的抑制作用。所报道的衍生物是通过相应酚类前体的磺酰胺化反应得到的,它们在苯磺酸盐片段与抑制剂尾部之间的间隔处带有 3,5-二芳基吡唑啉结构。吡唑啉是具有多种生物活性的生物优势骨架,例如抗增殖作用。这些衍生物被测试了对细胞质 hCA I 和 hCA II(非靶标同工酶)以及跨膜、肿瘤相关 hCA IX 和 hCA XII 酶(抗癌药物靶标)的抑制作用。一般来说,hCA I 没有被有效抑制,而许多低纳摩尔抑制剂对 hCA II(KIs 在 0.42-90.1 nM 范围内)、hCA IX(KIs 在 0.72-63.6 nM 范围内)和 hCA XII(KIs 在 0.88-85.2 nM 范围内)有很好的抑制作用。在吡唑啉环上的最佳取代片段包括对 CA II 的 3-芳基上的 4-磺酰胺基和 5-芳基上的卤素或 3-芳基上的甲氧基和 5-芳基上的 4-磺酰胺基;对 CA IX 和 CA XII 的 5-芳基的 3-或 4-位上的磺酰胺基和 3-芳基环的 4-位上的吸电子基团。